No Data
'Don't Be Scared of Heights': J.P. Morgan Suggests 2 Stocks to Buy
There’s no denying we’re in a bull market.
Here's Why Edgewise Therapeutics, Inc. (EWTX) Is a Great Momentum Stock to Buy
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32
RBC Capital analyst Leonid Timashev maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 48
Edgewise Therapeutics (EWTX) Receives a Buy From RBC Capital
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long